Tuesday, February 23, 2021

SPARC slips 2% after USFDA denies its cancer drug Taclantis application

SPARC has said that the company will review the FDAs response and decide on appropriate next steps soon.

from India Infoline News Service https://ift.tt/3dFZTHn
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)